Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Sun, Jong Mu; Choi, Yura; Ji, Jun Ho; Ahn, Jin‐Seok; Kim, K.-M.; Han, Jingjing; Ahn, Myung‐Ju; Park, K.

doi:10.1093/annonc/mdu504

Cited by 56 publications

(82 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D. 162 patients with PNI < 45 had worse prognosis than 757 patients with PNI ≥ 45 (8.7 vs. 11.0 months, P < 0.001). status before diagnosis in the prognosis of SCLC was also evaluated and the results confirmed that non-smokers with SCLC had better prognosis than smokers, and this was consistent with results from Korea (Sun et al 2015). Smoking status was especially useful as a predictor of long-term survival in this study.…”

Section: Discussionsupporting

confidence: 88%

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

Hong

Cui

Wang

et al. 2015

Tohoku J. Exp. Med.

271

239

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is an aggressive disease characterized by rapid growth and metastases. It has been recognized that the inflammation of the microenvironment plays a critical role in the development of malignancies. However, little is known about the role of multiple inflammatory and hematological markers in the prognosis of SCLC. The aim of this study was to determine the clinical significance of pre-treatment inflammation-based scores and characteristics as prognostic indicators for the survival of SCLC patients. A retrospective analysis of 919 SCLC cases was performed. Patients' characteristics and hematologic tests data at initial diagnosis were collected. The univariate analysis of all SCLC patients indicated that favorable prognostic factors were age ˂ 70 years, non-smokers, good performance status, limited disease and response to treatment. Moreover, univariate analysis of inflammation-based scores and other blood parameters showed that neutrophil-lymphocyte ratio ≥ 5, platelet-lymphocyte ratio ≥ 250, systemic immune-inflammation index (SII) ≥ 1,600 × 10 9 /L, prognostic nutritional index (albumin + 5 × lymphocyte) < 45, and elevated serum lactate dehydrogenase (LDH) predicted poor prognosis in SCLC patients. SII represents the score that is calculated as follows: platelet count × neutrophil count/lymphocyte count. In the multivariate analysis, SII, together with serum LDH, stage and response to therapy, were associated with overall survival (OS). This study demonstrated that the combination of platelet count and neutrophil-lymphocyte ratio could help to predict poor prognosis in SCLC. Our findings will facilitate the understanding of survival differences in SCLC patients in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 88%

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

Hong

Cui

Wang

et al. 2015

Tohoku J. Exp. Med.

271

239

View full text Add to dashboard Cite

show abstract

“…Compared with our study, a smaller number of SCLCs were included in their study and the histological heterogeneity might have affected their results. In addition, they used a semi-quantitative histological score, which was obtained by multiplying the percentage of reactive cells by the corresponding immunostaining intensity, as a continuous variable to evaluate immunohistochemical findings, whereas we used a binary variable, In our study, the proportion of never smokers was 24 %, which is much higher than that reported in non-Asian countries and contradicts the well-established strict relation between SCLC and cigarette smoking [14,15]. The prevalence of nonsmoking-related lung cancer, regardless of histological type, is known to be higher among Asian patients including Koreans than in non-Asian patients, and this could be explained by ethnic differences [15][16][17].…”

Section: Discussioncontrasting

confidence: 72%

“…In addition, 22 (79 %) of 28 never smokers included in this study were female. It has been reported that lung cancer develops more frequently in never-smoked women than never-smoked men [15,18]. This phenomenon suggests that there might be biological differences due to gender in the carcinogenesis of lung cancer.…”

Section: Discussionmentioning

confidence: 98%

Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) binding protein (4E-BP1) results in release of eIF4E, which sequentially relieves translational repression and enhances oncogenic protein synthesis. We assessed the expression of phosphorylated 4E-BP1 (p-4E-BP1) in small-cell lung cancer (SCLC) and its correlation with clinicopathological factors and patient survival. This study included 117 SCLCs, which comprised 108 primary and 9 metastatic tumor tissues. We performed immunohistochemical staining for p-4E-BP1 in 117 tumors and found that 77 (66 %) were positive for p-4E-BP1 with cytoplasmic and/or nuclear immunostaining. The positive rate of p-4E-BP1 staining was significantly higher in never smokers (p = 0.034) and metastatic tumor tissues (p = 0.027). Patients with p-4E-BP1-positive SCLC tended to have poor performance status, although the difference was not statistically significant (p = 0.087). High p-4E-BP1 expression was significantly correlated with worse overall survival (OS) in all cohorts (p = 0.016). After stratification by clinical stage, p-4E-BP1 expression showed a stronger relationship with OS in patients with limited disease (p = 0.008). In addition, when stratified by treatment status, p-4E-BP1 expression was still significantly associated with worse OS in a subgroup of patients who completed treatment (p = 0.021). Our results indicate that p-4E-BP1 expression could represent oncogenic potential and contribute to the progression and aggressiveness of SCLC, suggesting it could be a candidate prognostic biomarker of SCLC, especially in limited disease.

show abstract

“…The clinical characteristics and multigene mutation profiling of SCLC in never-smokers 35, 36 has been evaluated. The never-smokers with SCLC (50/391) had a better prognosis than smokers with SCLC in the Korean cohort.…”

Section: Genome Epigenome and Proteome Studiesmentioning

confidence: 99%

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn

Minna

Augustyn

et al. 2016

Journal of Thoracic Oncology

154

123

View full text Add to dashboard Cite

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Abstract: Never-smokers with SCLC are increasingly prevalent and have a better prognosis than smokers with SCLC in Korea. Our study warrants further investigation in this group.

Cited by 56 publications

References 19 publications

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer

Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Contact Info

Product

Resources

About